Something that appears to have been overlooked / not commented on so far is the relevance of the fact that MXC was one of 5 x international based MC companies that won this gig through a ‘competitive tender process’. I am sure there were many global MC based companies clamoring to get a foothold in the lucrative European market, via this Maltese MC tender opportunity.
Clearly, the in-house MC expertise and diverse range of our Medicinal, Cosmeceutical & Nutraceutical products and applications, was a big decider. Also, MXC has put in some pretty solid ground work (and expense) collaborating with institutes and universities around the world in a bid to promote and provide the many benefits of cannabis. This was a great strategic ploy that is now paying dividends, as displayed here via the tender ‘victory’.
Our selection as one of five successful tenders really puts us up there in the upper echelon of global MC producers and suppliers. It provides a very solid foundation for us moving further into established markets and creating new ones. This will result in more contracts, with associated rise in revenue and share-price.
“Under the agreement, MXC will be able to produce all THC (tetrahydrocannabinol) and CBD (cannabidiol) strains of medical cannabis. This widens MXC’s commercial opportunity to develop additional medical cannabis pharmaceutical products into key European and global markets, which derive benefits from both THC and CBD.” - (Finfeed article)
The ability to grow THC strains is essential for most MC applications. It is gratifying to see that Malta has included THC and recognizes its importance whereas others seem blinkered, wanting to be involved in only cannabis strains with very low THC content. Few seem to appreciate the importance that THC has in many medical applications to enhance the properties of CBD.
“According to the European Cannabis Report 2017, with a market of over 739 million people, and total healthcare spend of €1.49 trillion, Europe will be the largest medical cannabis market in the world. The estimated cannabis market value per year in the EU is €56.2 billion.”
On top of all this, MXC recently launched MGC Nutraceuticals, a new premium product line of CBD and hemp-enhanced nutraceutical products for retail customers. This new range immediately expands MXC’s consumer product offering into the global US$561 billion dietary supplement market with seven new high-end natural vegan products.
As others have pointed out, there is lots of imminent positive MXC news flow ahead …………….
Some other intriguing developments that have been brewing…
MXC has been making steady progress on three key project initiatives over the past six months in its collaboration with RMIT, including the strategic Library of Cannabinoids.
Partnership discussions have also begun between MXC, RMIT and leading Israeli research universities to deliver new medical cannabis technologies to critical markets.
Extraction of cannabinoids from last year’s Czech botanical production is set to be done and dusted in Prague this month — these will be used to manufacture new products.
MXC has applied for a medicinal cannabis research cultivation licence to the Australia’s Office of Drug Control (ODC).
The company’s research collaboration with the University of Ljubljana is progressing, with the experimental crop using MXC genetics now entering the middle of its flowering stage.
Potential strategic investment and JV opportunities are in the works with established licensed producers in Australia and North America.
Here is an excellent article on the recent accomplishments of MXC. It is longer than most but well worth the time.
This is all looking very positive for MXC. Great work!
(20min delay)